Changes in the interleukin-6/soluble interleukin-6 receptor axis in meningococcal septic shock

Critical Care Medicine

Volumn 33, Issue 8, 2005, Pages 1839-1844

  Pathan, Nazima ^a   John Williams, E ^a   Oragui, E Emanuelle ^a   Stephens, Alick C ^a   Levin, Michael ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Interleukin 6; Meningococcal septicemia; Septic shock; Soluble interleukin 6 receptor

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SCHOOL CHILD; SEPTIC SHOCK;

EID: 23844537808     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000174097.38764.C8     Document Type: Article

References (22)

1. Nadel S, Levin M, Habibi P: Treatment of meningococcal disease in childhood. In: Meningococcal Disease. K Cartwright (Ed). New York, Wiley, 1995, pp 207-244
2. Pathan N, Nadel S, Levin M: Pathophysiology and management of meningococcal septicaemia. J R Coll Physicians Lond 2000; 34: 436-444
3. Mercier JC, Beaufils F, Hartmann JF, et al: Hemodynamic patterns of meningococcal shock in children. Crit Care Med 1988; 16: 27-33
4. Carcillo JA, Fields AI: Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365-1378
5. van Deuren M, Brandtzaeg P, van Der Meer JW: Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13: 144-166
6. Parrillo JE, Burch C, Shelhamer JH, et al: A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76:1539-1553
7. Pathan N, Sandiford C, Harding SE, et al: Characterization of a myocardial depressant factor in meningococcal septicemia. Crit Care Med 2002; 30:2191-2198
8. Pathan N, Hemingway CA, Alizadeh AA, et al: Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004; 363:203-209
9. Hack CE, De Groot ER, Felt-Bersma RJ, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74:1704-1710
10. Calandra T, Gerain J, Heumann D, et al: High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991; 91:23-29
11. Waage A, Brandtzaeg P, Halstensen A, et al: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169:333-338
12. van Deuren M, van der Ven-Jongekrijg J, Bartelink AK, et al: Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995; 172:433-439
13. Kinugawa K, Takahashi T, Kohmoto O, et al: Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. Circ Res 1994; 75:285-295
14. Sugishita K, Kinugawa K, Shimizu T, et al: Cellular basis for the acute inhibitory effects of IL-6 and TNF- alpha on excitation-contraction coupling. J Mol Cell Cardiol 1999; 31:1457-1467
15. Frieling JT, van Deuren NM, Wijdenes J, et al: Interleukin-6 and its soluble receptor during acute meningococcal infections: effect of plasma or whole blood exchange. Crit Care Med 1996; 24:1801-1805
16. Pollack MM, Ruttimann UE, Getson PR: Pediatric Risk of Mortality (PRISM) score. Crit Care Med 1988; 16:1110-1116
17. Pollack MM, Patel KM, Ruttimann UE: PRISM III: An updated Pediatric Risk of Mortality score. Crit Care Med 1996; 24: 743-752
18. Kumar A, Thota V, Dee L, et al: Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183:949-958
19. Ostermann H, Kratz-Albers K, Mesters RM, et al: Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients. J Infect Dis 1997; 176:825-828
20. Mitsuyama K, Toyonaga A, Sasaki E, et al: Soluble interleukin-6 receptors in inflammatory bowel disease: Relation to circulating interleukin-6. Gut 1995; 36: 45-49
21. Honda M, Yamamoto S, Cheng M, et al: Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992; 148:2175-2180
22. De Benedetti F, Massa M, Pignatti P, et al: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93:2114-2119